Company intelligence / Profile preview

Endomet Biosciences

Grand Rapids, Michigan, United States

Ownership: Private
Development stage: Other

Overview

Endomet Biosciences is a biotechnology company focused on developing innovative treatments for endometriosis by targeting the underlying metabolic dysregulation of the disease. The company's approach centers on identifying and modulating specific metabolic pathways that drive the proliferation and survival of endometriotic lesions. By focusing on non-hormonal mechanisms, Endomet Biosciences aims to provide more effective and better-tolerated therapeutic options for patients suffering from this chronic condition. Their research is currently in the pre-clinical stage, with a focus on validating novel small molecule candidates.

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Endomet Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endomet Biosciences.

Explore the full profile